MARKET

TRDA

TRDA

Entrada Therapeutics, Inc.
NASDAQ
7.15
-0.39
-5.17%
Closed 18:00 06/25 EDT
OPEN
7.55
PREV CLOSE
7.54
HIGH
7.71
LOW
7.02
VOLUME
244.91K
TURNOVER
0
52 WEEK HIGH
16.45
52 WEEK LOW
4.930
MARKET CAP
277.57M
P/E (TTM)
-1.7885
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TRDA last week (0615-0619)?
Weekly Report · 4d ago
Weekly Report: what happened at TRDA last week (0608-0612)?
Weekly Report · 06/15 09:18
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 06/10 21:05
Entrada Therapeutics Stockholders Approve Directors and Equity Plans
TipRanks · 06/10 20:52
Entrada Therapeutics shareholders approved amendments to 2021 incentive plan, employee stock purchase plan
PUBT · 06/10 20:07
Entrada Therapeutics Price Target Cut to $17.00/Share From $20.00 by Guggenheim
Dow Jones · 06/08 14:28
Entrada Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 06/08 14:28
Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $17
Benzinga · 06/08 14:18
More
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.

Webull offers Entrada Therapeutics Inc stock information, including NASDAQ: TRDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRDA stock methods without spending real money on the virtual paper trading platform.